Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment

Panelists discuss how the patient’s journey with multiple myeloma begins with an initial diagnosis followed by first-line treatments and how this informs the decision to consider chimeric antigen receptor T-cell therapy as a subsequent option in their treatment path.

EP: 1.Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient

Now Viewing

EP: 2.Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment

EP: 3.CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation

EP: 4.CAR-T Therapy Journey: From Cell Collection to Managing Challenges

EP: 5.Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment

EP: 6.Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care

EP: 7.Navigating Recovery: CAR-T Cell Therapy Experience

EP: 8.Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care

EP: 9.Navigating My Myeloma Journey: Insights and Advice on CAR-T Therapy

EP: 10.The Future of CAR-T: Advancing Myeloma Treatment Strategies

Video content above is prompted by the following:

• How did your health care team introduce the possibility of chimeric antigen receptor (CAR) T-cell therapy as an option after your previous lines of therapy?
• What factors were considered when deciding to move to CAR T-cell therapy in your treatment journey?

Recent Videos